Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
NCT04722601Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, CC-486 in follicular lymphoma (FL), sponsored by University of Chicago. Started Sep 2021; status: terminated.
02
Drugs
venetoclaxCC-486
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04722601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722601.